INCYTE CORP
Nasdaq: INCY·Wilmington, Delaware·CIK 0000879169
- Price
- $120.27
- Base IV
- $98.43
Valuation snapshot
At $120.27, the price sits between our base case ($98.43) and bull case ($163.15).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $98.43
- 82% of the price · range $50.59–$163.15
- Price vs base case
- 22% above
- $120.27 against $98.43
- Base case · our researched forecast, 2026-11-13See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $50.59 to bull $163.15. Values per share.
Price against each value
- Bear case
- $50.59
- Price 138% above
- No growth
- …
- —
- Base case
- $98.43
- Price 22% above
What does Incyte do?
Incyte Corp develops and commercializes pharmaceuticals to treat patients with hematologic cancers, such as myelofibrosis and chronic myeloid leukemia, and inflammatory conditions.
It brought in $6B of sales in the 12 months to Sep 2026.
Led by William (Bill) J. Meury, Chief Executive Officer and Director since 2025. Incyte Corp Form 8-K (Item 5.02) – Executive leadership title changes; Meury remains CEO
- Industry
- Healthcare
- Based in
- Wilmington, Delaware
- Trades on
- Nasdaq as INCY
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 7¢ was left as profit after every cost, interest and tax. The biggest cost is research and development, 57¢ of every dollar.
- Making what it sells7¢
- Research and development57¢
- Sales, marketing and admin24¢
- Everything else it takes to operate1¢
- Tax7¢
- Left as profit7¢
- Interest and other income came back in+3¢
Who pays Incyte, and for what?
Incyte discovers, develops and sells medicines for blood cancers, other cancers, and inflammatory and autoimmune diseases. It earns revenue from its own medicine sales, royalties on medicines commercialized by partners, and milestone and contract payments.
Its medicines are sold to specialty and retail pharmacies, distributors and wholesalers; partner companies pay royalties and other collaboration-related amounts.
JAKAFI
60%U.S. sales of ruxolitinib for certain blood disorders and graft-versus-host disease.
OPZELURA
13%Sales of ruxolitinib cream for atopic dermatitis and vitiligo.
ICLUSIG
3%Sales of ponatinib, principally in Europe, for certain forms of leukemia.
PEMAZYRE
2%Sales of pemigatinib for certain bile duct and blood cancers.
MINJUVI/MONJUVI
3%Sales of tafasitamab for certain types of lymphoma.
Other reported revenue
20%Includes NIKTIMVO and ZYNYZ sales, royalties from partner medicines, and milestone and contract revenue.
Where its work physically happens, beyond headquarters:
- Yverdon biologics production facility — Yverdon, Switzerland. The facility manufactures MONJUVI/MINJUVI drug substance and provides Incyte with internal biologics production capacity.
- Morges European headquarters — Morges, Switzerland. Incyte conducts European clinical development and commercial operations here; Europe generated $323.7 million of revenue in 2025.
- Chadds Ford commercial office — Chadds Ford, United States. Incyte leases approximately 116,000 square feet here for an office that houses its U.S. oncology and dermatology teams.
- Tokyo office — Tokyo, Japan. The office supports Incyte’s clinical development and commercial operations in East Asia.
- Montreal Canadian headquarters — Montreal, Canada. Incyte identifies Montreal as its Canadian headquarters for clinical development and commercial operations.
How is the business doing?
Sales grew from $2.7B in 2020 to $5.1B in 2025, about 14% a year.
Running the business leaves about 10¢ of each sales dollar as operating profit, up from 10¢ in 2020.
What does management say it's aiming for?
Incyte says it aims to discover and advance new treatments for significant unmet medical needs.
“discovering and advancing novel therapeutics that address significant unmet medical needs”
Who is responsible for the plan?
- William (Bill) J. MeuryChief Executive Officer and Director
Leads Incyte as Chief Executive Officer and sits on its Board of Directors. As CEO he is accountable for the whole company, which earns most of its revenue from product sales of medicines such as Jakafi and Opzelura and also earns product royalties.
- Mohamed Issa, Pharm.D., MBAExecutive Vice President and Head of U.S. Commercial
Leads Incyte's combined U.S. commercial organization, which covers both the oncology and immunology businesses. Incyte earns most of its product revenue from U.S. sales of medicines such as Jakafi and Opzelura, and his organization handles those sales.
- Pablo J. Cagnoni, M.D.President, Incyte and Global Head of Research and Development
Oversees Incyte's global research and development work and is also responsible for enterprise-wide strategy and operations. The R&D organization discovers and develops the hematology, oncology and inflammation/autoimmunity medicines that Incyte commercializes or licenses for royalties.
Roles checked November 13, 2026.
What management says it is working on now:
Advance focused discovery programs
The company says it concentrates research on targeted oncology, myeloid diseases and dermatology, and aims to move lead candidates quickly into trials that test their potential.
Incyte 2025 Form 10-KGrow and support its medicine portfolio
Incyte says it is expanding marketing, medical and operational capabilities to support recent launches and prepare for possible approvals.
Incyte 2025 Form 10-KBuild revenue beyond JAKAFI
Management says new products are needed to support revenue growth and offset the expected effect of JAKAFI's loss of patent exclusivity in 2028.
Incyte 2025 Form 10-K
What's changing right now?
Growth is slowing. In Q3 2026 it sold 14% more than a year earlier. The year before, quarters averaged 27%.
Its operating margin is narrower than a year ago: a loss of 45¢ per sales dollar, against 32¢.
Since Oct 2026 the share price has risen 3%, from $116.80 to $120.27.
Recently
October 29, 2026
Jakafi net sales, quarterly changed to $827.0M
Incyte Q3 2026 results (8-K)December 31, 2025
Annual R&D Expense to Total Revenue Ratio changed to 38.6%
Incyte 2025 Form 10-K Consolidated Statements of OperationsDecember 31, 2025
Jakafi Annual US Net Product Revenues changed to $3.1B
Incyte 2025 Form 10-K and Earnings Release
Coming up
Mid-2026
Potential JAKAFI XR decision and launch
The company expects a regulatory decision and possible launch of its once-daily ruxolitinib formulation.
Incyte 2025 Form 10-KET in mid-2026; MF in second half of 2026
INCA033989 Phase 3 trials
Incyte expects to start Phase 3 trials of its investigational treatment in essential thrombocythemia and myelofibrosis.
Incyte 2025 Form 10-KEurope by end-2026; U.S. by early 2027
Potential povorcitinib approvals for HS
The company expects a possible European approval and a possible U.S. approval for povorcitinib in hidradenitis suppurativa, subject to regulatory review.
Incyte 2025 Form 10-KVitiligo by mid-2026; PN Q4 2026; asthma H2 2026
Povorcitinib Phase 3 results
The company anticipates results from Phase 3 studies in vitiligo and prurigo nodularis, plus proof-of-concept data in asthma.
Incyte 2025 Form 10-K
Our own estimate moved too: the base case went from $91.79 to $98.43 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Dependence on JAKAFI
JAKAFI generated a large share of revenue, and the company expects sales to begin declining after its patent exclusivity ends in 2028. Lower sales could limit funding for other research and launches.
From the company's own filingsWould hit how fast sales growIncyte 2025 Form 10-K
Competition from other medicines
Larger drug companies and smaller biotech firms may develop treatments that are more effective, safer, easier to use or less expensive, reducing demand for Incyte's products.
From the company's own filingsWould hit how fast sales growIncyte 2025 Form 10-K
Coverage and pricing pressure
Insurers and government programs may limit coverage, require discounts or reduce reimbursement. This could make medicines less accessible to patients and lower sales or profitability.
From the company's own filingsWould hit how fast sales growIncyte 2025 Form 10-K
Clinical and approval uncertainty
Drug development takes time and may fail; regulators can request more studies or decline approval. Delays or unsuccessful trials could prevent expected products from reaching patients.
From the company's own filingsWould hit how fast sales growIncyte 2025 Form 10-K
Safety and regulatory requirements
New safety concerns or failures to meet ongoing rules could lead to warnings, restricted use, added studies, recalls or loss of approval, harming sales and increasing costs.
From the company's own filingsWould hit how fast sales growIncyte 2025 Form 10-K
Distribution channel concentration
Incyte relies on a limited number of specialty pharmacies and wholesalers for much of its medicine distribution. Losing a major channel could interrupt sales and add replacement costs.
From the company's own filingsWould hit how fast sales growIncyte 2025 Form 10-K
Jefferies estimates a Jakafi revenue hole of about $2.6B after exclusivity is lost, which could mean deeper declines in years 3 and 4.
From our researchWould hit how fast sales growTipRanks/The Fly
The 2026 operating-expense guidance was raised to $4.915-4.995B, including the Vega IPR&D charge and continued latarcibart Phase 3 spending.
From our researchWould hit how much of each sale it keepsMarketBeat Q2 call highlights
Is it a good business?
From 2016 to 2025 it earned between -42% and 64% on the capital invested in it, a median of 27%. Its cost of capital in the latest valuation is 8.0%; returns were above it in 6 of the 10 years.
From 2016 to 2025 it earned between -19% and 25% on its shareholders' equity, a median of 10%.
Over 10 years its operating margin ranged from 16¢ to 29¢ per sales dollar, a median of 15¢. Gross margin ran from 93¢ to 95¢.
Cost of capital 8.0%
The number of shares grew 13% from 2016 to 2020, so each share owns a smaller slice of the business.
It holds $3.2B more in cash than it owes.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $120.27. Our put its value between $50.59 and $163.15, with $98.43 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $50.59
This scenario assumes Incyte's recent run of double-digit sales growth fades quickly, its biggest drug loses much of its sales to cheaper copies from 2028, and its newer medicines only partly make up the difference.
Base case, $98.43
This scenario assumes Incyte keeps growing for about two more years on newer skin and blood-disease drugs, takes a temporary dip when its biggest drug faces cheaper copies around 2028, and then returns to modest growth.
Bull case, $163.15
This scenario assumes Incyte's fast-growing newer medicines and upcoming launches largely make up for its biggest drug losing patent protection around 2028, so sales dip only briefly and then keep climbing.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 22%
For Incyte to be worth today's $120.27, sales would need to grow about 6.3% a year. We assume 0.9%. Over the last 5 years, sales grew 15.6% a year.
Or, if sales grow 0.9% as we assume, the price works with a profit margin of 34.2% (we assume 27.0%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 6.3% a year?
Try your own numbersWe're not very sure of this range: it scores 38 out of 100 on our checks. The weakest point is historical stability.
Test the assumptions
Our base value of $98.43 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average0.9%
- Operating margin27.0%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$98.43 -18.2%


